Compare WD 40 Company (WDFC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
WD 40 Company vs State Street SPDR S&P Biotech ETF — how do they compare? WD 40 Company trades at $199.54 (market cap $2.71B), while State Street SPDR S&P Biotech ETF trades at $159.9. The key difference: WD 40 Company pays a 2.02% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, WD 40 Company nearer its low. Which is the better fit depends on your goals.
| WDFC | XBI | |
|---|---|---|
Market Cap | $2.71B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $264.91 | $169.55 |
52-Week Low | $187.52 | $93.43 |
Enterprise Value | $2.76B | — |
Dividend Yield | 2.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
WDFC trades at $201.73, down 2.81% today, with a bearish technical signal but strong fundamentals. Recent earnings show mixed results with a Q4 2025 miss but Q1 and Q2 2026 beats. The company maintains robust profitability with a 55.82% gross margin and 13.22% net margin. News highlights strong Q3 2026 performance and strategic growth initiatives including global expansion and digital transformation.
Outlook is cautiously optimistic with solid brand loyalty and growth potential, but risks include input cost pressures and valuation concerns. Analyst consensus is mixed with a 'Hold' majority. The stock's current price near support at $199 suggests potential stability if fundamentals hold.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
